A nationwide multicentre, open-label study of six months avelumab maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after at least 4 cycles of first-line platinum-containing chemotherapy and the opportunity to re-treat
Latest Information Update: 26 Apr 2021
At a glance
- Drugs Avelumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms AVELUMAB SHORT MAINTENANCE
- 26 Apr 2021 New trial record